New drug combo tested to shrink breast tumors before surgery
NCT ID NCT05525767
Summary
This study is testing whether adding the drug bevacizumab to standard chemotherapy helps shrink tumors more effectively before surgery in people with early or locally advanced HER2-negative breast cancer. The goal is to see if this combination leads to better outcomes, like completely eliminating cancer cells in the removed tissue and allowing more patients to have breast-conserving surgery. It will involve about 75 participants across multiple hospitals in China.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.